Lipid nanoparticles have become the gold standard for delivering genetic material into cells. They proved their worth as the backbone of COVID-19 vaccines, protecting billions of people worldwide. Now researchers want to weaponize them against cancer, inflammatory diseases, and genetic mutations using therapeutic mRNA and CRISPR systems. But there's a problem: what works brilliantly in the lab fails miserably in the human body.
A team at Biohub discovered the bottleneck wasn't the nanoparticles themselves. It was the cells. When researchers grew cells in conditions mimicking human blood plasma instead of standard nutrient-rich lab media, nanoparticle uptake collapsed by 50 to 80 percent. The cells were starving for something.
The answer turned out to be stunningly simple. Adding three amino acids,methionine, arginine, and serine,alongside the nanoparticles transformed performance. Protein production from delivered mRNA jumped 5 to 20-fold. CRISPR gene editing efficiency soared from roughly 25 percent to nearly 90 percent in a single dose.
Daniel Zongjie Wang and Shana O. Kelley led the research, which appears in Science Translational Medicine. They approached the problem differently than the rest of the field. For years, scientists had tested hundreds of lipid combinations and used artificial intelligence to hunt for better nanoparticle designs. Progress stalled. Wang's team instead asked whether cells themselves were the limiting factor, whether their metabolic state determined whether they would swallow nanoparticles or reject them.
They found that several amino acid-related metabolic pathways went dormant when cells operated under conditions closer to those inside the human body. The cells had fewer nutrients available. By supplementing with the right amino acids, researchers essentially flipped a metabolic switch that made cells ravenous for nanoparticles.
From mice to medicine
The team tested the approach in animal disease models. In mice suffering from acetaminophen-induced acute liver failure, survival jumped from 33 percent with standard treatment to 100 percent when the amino acid supplement was added. Therapeutic protein levels nearly tripled, while markers of liver damage and inflammation dropped to near-normal.
A CRISPR experiment in mouse lungs showed similar dramatic gains. Without supplementation, gene editing reached 20 to 30 percent efficiency. With the amino acids, efficiency climbed to 85 to 90 percent. That kind of improvement matters for diseases like cystic fibrosis, where you need to fix enough cells in lung tissue to make a clinical difference.
What makes this discovery especially practical is that nothing needs to be reinvented. The three amino acids are already mass-produced and considered safe. They work with any nanoparticle design, any genetic payload, and across multiple delivery routes: muscle injection, lung delivery, and intravenous infusion all showed the same boost. The supplement could simply be mixed into existing formulations.
Kelley, president of bioengineering at Biohub, put it bluntly: "Any LNP formulation being developed today could potentially benefit from our approach." That statement hints at how broad the implications are. Every mRNA therapy and gene-editing treatment in development could become substantially more effective without months of additional research and regulatory hurdles.
The field has been stuck in a redesign loop for years, tinkering with nanoparticle chemistry while ignoring the biology on the receiving end. These researchers flipped the lens and found the real answer was hiding inside the cell.
Author Jessica Williams: "This is the kind of elegant, practical solution that actually moves treatments from the lab to patients, and it's waiting on the shelf already."
Comments